HomeCompareADMS vs QYLD

ADMS vs QYLD: Dividend Comparison 2026

ADMS yields 24.33% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADMS wins by $69.5K in total portfolio value
10 years
ADMS
ADMS
● Live price
24.33%
Share price
$8.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$94.9K
Annual income
$10,445.94
Full ADMS calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — ADMS vs QYLD

📍 ADMS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADMSQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADMS + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADMS pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADMS
Annual income on $10K today (after 15% tax)
$2,068.13/yr
After 10yr DRIP, annual income (after tax)
$8,879.05/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, ADMS beats the other by $4,068.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADMS + QYLD for your $10,000?

ADMS: 50%QYLD: 50%
100% QYLD50/50100% ADMS
Portfolio after 10yr
$60.1K
Annual income
$8,052.63/yr
Blended yield
13.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADMS right now

ADMS
Analyst Ratings
6
Buy
7
Hold
2
Sell
Consensus: Hold
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADMS buys
0
QYLD buys
0
No recent congressional trades found for ADMS or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADMSQYLD
Forward yield24.33%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$94.9K$25.4K
Annual income after 10y$10,445.94$5,659.31
Total dividends collected$59.3K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ADMS vs QYLD ($10,000, DRIP)

YearADMS PortfolioADMS Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$13,133$2,433.09$10,352$1,192.36+$2.8KADMS
2$17,039$2,986.35$10,830$1,347.57+$6.2KADMS
3$21,852$3,621.00$11,460$1,539.07+$10.4KADMS
4$27,722$4,340.18$12,275$1,777.84+$15.4KADMS
5$34,809$5,145.80$13,323$2,078.95+$21.5KADMS
6$43,284$6,038.47$14,667$2,463.34+$28.6KADMS
7$53,331$7,017.47$16,396$2,960.57+$36.9KADMS
8$65,145$8,080.76$18,631$3,612.97+$46.5KADMS
9$78,930$9,225.06$21,548$4,482.15+$57.4KADMS
10$94,901$10,445.94$25,398$5,659.31+$69.5KADMS

ADMS vs QYLD: Complete Analysis 2026

ADMSStock

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Full ADMS Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this ADMS vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADMS vs SCHDADMS vs JEPIADMS vs OADMS vs KOADMS vs MAINADMS vs XYLDADMS vs JEPQADMS vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.